EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sacituzumab Govitecan initial dose reduction in polish patients with metastatic triple-negative breast cancer: impact on efficacy and safety

Małgorzata Pieniążek, Marcin Kubeczko, Manuela Las-Jankowska, Anna Polakiewicz-Gilowska, Aleksandra Łacko, Michał Jarząb, Zuzana Bielčiková, Renata Pacholczak-Madej, Miroslawa Püsküllüoğlu

Cancer Chemotherapy and Pharmacology · 2025-12 · 95 (1)

DOI: 10.1007/s00280-025-04823-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 04.10.2025. Verfasst von Małgorzata Pieniążek und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Wrocław Medical University, Plac Hirszfelda 12, Wrocław, 53-413, Poland. pieniadzgosia@interia.pl. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Antibodies, Monoclonal, Humanized, Camptothecin. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sacituzumab govitecan (SG) is approved for metastatic triple-negative breast cancer in ≥ 2 line setting at 10 mg/kg IV on Days 1 and 8 (21-day cycle). Trials confirmed its superiority over 8 mg/kg with manageable safety. In practice, precautionary dose reductions are used despite no formal guidance. In Poland, fixed 200 mg vials and unreimbursed drug waste lead to early dose adjustments.

Methods

This retrospective study evaluated the impact of initial SG dose reduction on treatment outcomes and tolerability in Polish patients. Medical records provided data on baseline features, treatment, survival, and safety. Kaplan-Meier and chi-square tests were used for survival and group comparisons. A multivariate Cox model assessed the independent effect of dose reduction on overall survival (OS) and progression-free survival (PFS). Significance was set at p < 0.05.

Results

Among 83 patients (median age 55, range 30–86), initial dose reductions ≥ 10% were observed in 16 patients (19.3%), including 9 (10.8%) with dose reduced ≥ 20%. Administrative adjustments (reductions > 10% to flat doses of 200 mg multiplications) accounted for 18.1% of the entire cohort. Grade ≥ 2 and ≥ 3 adverse events occurred in 83.1% and 56.6%, respectively. In a multivariate analysis, a ≥ 20% initial dose reduction remained an independent predictor of shorter PFS (HR: 2.6; 95% CI: 1.1–6.6; p = 0.04) and OS (HR: 6; 95% CI: 2–17.5; p = 0.001). Initial dose reduction did not affect toxicity.

Conclusions

In this preliminary report initial dose reduction of SG negatively impacted PFS and OS without reducing toxicity, highlighting the need for further studies and dosing policy adjustments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsAntibodies, Monoclonal, HumanizedCamptothecinHumansFemaleMiddle AgedAgedRetrospective StudiesAdultAged, 80 and overPolandProgression-Free SurvivalDose-Response Relationship, DrugImmunoconjugates

Stichwörter der Autor:innen

Dose reductionMetastasesReal world dataSacituzumab govitecanTriple negative breast cancer

Substanzen

Antibodies, Monoclonal, Humanizedsacituzumab govitecanCamptothecinImmunoconjugates

Autor:innen und Institutionen

  • Department of Oncology, Wrocław Medical University, Plac Hirszfelda 12, Wrocław, 53-413, Poland. pieniadzgosia@interia.pl.
  • Lower Silesian Comprehensive Cancer Center, Plac Hirszfelda 12, Wrocław, 53-413, Poland. pieniadzgosia@interia.pl.
  • Breast Cancer Unit, Gliwice Branch, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice, 44-102, Poland. marcin.kubeczko@gliwice.nio.gov.pl.
  • Surgical Oncology, Oncology Centre, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, 85-067, Poland.
  • Department of Clinical Oncology, Oncology Center-Prof Franciszek Lukaszczyk Memorial Hospital, Bydgoszcz, 85-796, Poland.
  • Breast Cancer Unit, Gliwice Branch, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice, 44-102, Poland.

Zitieren

APA

Pieniążek, M., Kubeczko, M., Las-Jankowska, M., Polakiewicz-Gilowska, A., Łacko, A., Jarząb, M., Bielčiková, Z., Pacholczak-Madej, R., & Püsküllüoğlu, M. (2025). Sacituzumab Govitecan initial dose reduction in polish patients with metastatic triple-negative breast cancer: impact on efficacy and safety. Cancer Chemotherapy and Pharmacology, 95(1). https://doi.org/10.1007/s00280-025-04823-3

Vancouver

Pieniążek M, Kubeczko M, Las-Jankowska M, Polakiewicz-Gilowska A, Łacko A, Jarząb M, et al. Sacituzumab Govitecan initial dose reduction in polish patients with metastatic triple-negative breast cancer: impact on efficacy and safety. Cancer Chemotherapy and Pharmacology. 2025;95(1). doi:10.1007/s00280-025-04823-3

BibTeX
@article{Pieniek2025,
  author = {Pieniążek, Małgorzata and Kubeczko, Marcin and Las-Jankowska, Manuela and Polakiewicz-Gilowska, Anna and Łacko, Aleksandra and Jarząb, Michał and Bielčiková, Zuzana and Pacholczak-Madej, Renata and Püsküllüoğlu, Miroslawa},
  title = {Sacituzumab Govitecan initial dose reduction in polish patients with metastatic triple-negative breast cancer: impact on efficacy and safety},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2025},
  volume = {95},
  number = {1},
  doi = {10.1007/s00280-025-04823-3}
}
Kostenlos starten →